Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

The introduction of novel agents has led to major improvements in clinical outcomes for
patients with multiple myeloma. To shorten evaluation times for new treatments, health …

Flow cytometry has become a highly valuable method to monitor minimal residual disease
(MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple …

PURPOSE Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …